Detailed Narrative
Strong Q4 and FY26 Performance Driven by Volume Growth
Rossari Biotech concluded FY26 with robust performance, reporting its highest-ever quarterly revenue of ₹684.9 crore in Q4, an 18% YoY increase. Full-year revenue reached ₹2,396.4 crore, marking a 15% YoY growth, primarily driven by volume expansion. All three business segments—HPPC, Textiles, and AHN—contributed to this growth, with Q4 seeing increases of 18%, 20%, and 14% respectively. Exports also demonstrated strong momentum, growing 11% YoY in FY26.
Strategic Focus on R&D, Innovation, and Capacity Expansion
The company continues to prioritize R&D and innovation, evolving towards broader platform technologies. A new R&D facility in Navi Mumbai has been established to consolidate existing operations and accelerate product development, particularly in sustainable chemistries like biosurfactants. On the manufacturing front, Unitop commissioned additional ethoxylation capacity at Dahej, increasing total installed capacity to 66,000 MTPA, with current utilization levels at 90-100%.
EBITDA Margin Management Amidst Cost Pressures
Despite strong revenue growth, EBITDA margins experienced slight compression, falling to 11.3% in Q4 FY26 from 12% in the prior year, and to 11.9% for FY26 from 12.7% in FY25. This was attributed to a less favorable sales mix and significant raw material price increases (25-30% in March). However, the company successfully passed on these cost increases to customers from April. Excluding the institutional and B2C businesses, the core B2B operations maintained a healthy EBITDA margin of 14% for the year.
Rephased CAPEX and Debt Reduction Strategy
Rossari Biotech has rephased its earlier announced CAPEX of ₹192 crore, opting for a more calibrated approach. The planned CAPEX for FY27 is now estimated between ₹50-75 crore, focusing on high-margin areas such as pharma and aroma chemicals. The company also aims to significantly reduce its debt, targeting to become debt-free within the next 18 months, supported by cash flow generation and the divestment of non-core assets, including the recent sale of office space for ₹19 crore.
Future Growth Drivers and International Market Expansion
The company anticipates sustaining a minimum of 15% plus revenue growth in FY27, driven by new capacities, expected Ethylene Oxide availability from Reliance by Q3, and strategic focus on high-growth, high-margin segments like pharma, agro, and oil & gas. International expansion remains a key priority, with plans to strengthen manufacturing footprint in Saudi Arabia and ramp up exports to regions like Latin America, Southeast Asia, and Turkey. The Thailand plant is expected to contribute meaningfully from Q2 FY27.